Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-02

Clinical Trial Update: Anti-epileptogenic Effects of Eslicarbazepine Acetate [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anti-epileptogenic effects of eslicarbazepine acetate in post-stroke epilepsy completed, with results posted on 2025-05-02.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • eslicarbazepine acetate (eslicarbazepine acetate)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Post Stroke Epilepsy | Phase 2 | Status: COMPLETED | Results posted: 2025-05-02